# Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

> **NCT03749460** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 20 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Lung
- Salivary Gland Carcinoma
- Stage IV Major Salivary Gland Cancer AJCC v8
- Stage IVA Major Salivary Gland Cancer AJCC v8
- Stage IVB Major Salivary Gland Cancer AJCC v8
- Stage IVC Major Salivary Gland Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT03749460
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2022-11-05
- **Final completion:** 2023-11-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749460, "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03749460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*